In a significant development for those battling Type 2 diabetes, Dexcom has introduced the Stelo, an over-the-counter continuous glucose monitor (CGM) designed to provide more affordable and accessible glucose monitoring for individuals with Type 2 diabetes. Unlike traditional CGMs, which are predominantly used by Type 1 diabetics, the Stelo is specifically tailored for those managing Type 2 diabetes without insulin dependency.
A New Era in Glucose Monitoring
Dexcom’s Stelo, one of only three FDA-approved over-the-counter CGMs, marks a shift in diabetes management technology. Traditionally, CGMs have been a vital tool for Type 1 diabetics, who require constant monitoring of their blood sugar levels due to their body’s inability to produce insulin. However, the Stelo is aimed at the millions living with Type 2 diabetes, a condition that develops gradually as the body becomes resistant to insulin. While some Type 2 diabetics require insulin, the majority manage their condition through lifestyle changes and oral medications.
The introduction of OTC CGMs like the Stelo offers a promising tool for individuals looking to achieve better glucose control, potentially reducing or even eliminating the need for medication. For those in the prediabetic stage, the Stelo could play a crucial role in reversing the condition by providing real-time insights into how diet and exercise impact glucose levels.
Accessibility and Pricing
Affordability has long been a barrier to CGM adoption among Type 2 diabetics, as these devices are often not covered by insurance unless insulin is prescribed. Dexcom aims to break down this barrier with the Stelo. Available at $99 for a 30-day supply or $89 per month with a subscription, the Stelo is a more budget-friendly option, with the added benefit of being eligible for Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA).
User Experience and App Integration
The Stelo offers a user-friendly experience similar to platforms like Nutrisense, which cater to non-diabetics seeking to optimize their metabolic health. The device is easy to apply and relatively painless, despite its needle-based design. The accompanying app guides users through the setup process and provides real-time glucose monitoring after a brief calibration period. Users can sync their data with iOS and Android health platforms, log meals, and receive alerts when their glucose levels spike.
However, the app is not without its drawbacks. Some users have reported delays in receiving alerts, which could be problematic for those needing timely information. Additionally, the app lacks long-term historical data tracking, making it challenging to monitor trends over extended periods. There are also concerns about the manual logging process for meals, which could be streamlined by integrating with other health-tracking apps.
A Step Toward Better Health Management
Despite its early-stage hiccups, the Stelo represents a significant step forward in making CGM technology more accessible to those with Type 2 diabetes. The ability to monitor glucose levels continuously can empower users to make informed decisions about their health and potentially prevent the progression of diabetes.
As the technology evolves, Dexcom’s Stelo could become an essential tool in the broader effort to manage and prevent Type 2 diabetes. While the market for CGMs continues to grow, particularly among wellness enthusiasts, Dexcom’s focus on providing a practical solution for those who need it most is a promising sign for the future of diabetes management.
